When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst ...

International Assets Investment Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 98 ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note ...

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and financing for a novel long-acting clinical ...